China Grand to fund Sirtex buy with rights issue
China Grand Pharmaceutical and Healthcare Holdings has opted to pay for its acquisition of Australia-listed Sirtex Medical with a HK$2.9bn ($370m) rights issue.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts